A Study of BGB-11417 in Participants With Myeloid Malignancies

To join this study, doctors will check if you meet certain requirements. You must have a confirmed diagnosis of acute myeloid leukaemia (AML, but not a specific type called acute promyelocytic leukaemia), myelodysplastic syndromes (MDS), or myelodysplastic/myeloproliferative neoplasm (MDS/MPN). You also need to be generally well enough to take part, as measured by a common health check. Your organs, like your kidneys and liver, need to be working well enough, and doctors will assess that you are expected to live for more than 12 weeks.

There are also some reasons why you might not be able to join. For example, if you have acute promyelocytic leukaemia, or if your cancer has spread to your brain or spinal cord. If you've had certain other cancers recently, or if you have specific blood conditions like myelofibrosis that aren't the focus of this study, you wouldn't be able to participate. Also, if you've previously been treated with a similar type of drug to BGB-11417, called a B-cell lymphoma-2 inhibitor, you wouldn't be eligible.

If you decide to take part in this study, you would receive the study drug, BGB-11417, which might be given alone or with azacitidine. You would have regular visits to the hospital or clinic for various checks and tests. These tests could include blood tests, health assessments, and scans to monitor your health and how the treatment is working. Doctors and nurses will explain how often these visits will be. The study will continue for a period, and you will be followed up to see how you are doing after treatment. The exact total duration often depends on how the treatment is affecting you and generally can last for several months or longer.